Abstract
Ruxolitinib cream has demonstrated significant promise in both approved and off-label dermatological indications. Its localized action, rapid symptom relief, and favourable safety profile make it an attractive alternative to systemic treatments. However, current evidence is limited by small sample sizes, short follow-up periods, and unoptimized dosing protocols. Addressing these gaps through larger-scale, long-term research will be critical to understanding its full potential as a safe and effective therapy for diverse inflammatory and autoimmune skin diseases.
Keywords
- Autoimmune Bullous Skin Diseases
- ruxolitinib
- off-label drug use
- dermatological indications
- inflammatory skin diseases
- autoimmune skin disease
- JAK inhibitors
- local therapy
- dosing regimen
- drug safety
- Open access
Source
Published in Canadian dermatology today.. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
